Friday, November 2, 2018
AbbVie sees FY18 Imbruvica global revenue above $3.5B, US sales above $2.9B
Sees FY18 international Humira revenue approaching $6.3B. Sees FY18 Humira U.S. revenue $13.7B. Continues to see global HCV sales above $3.5B. Sees FY18 adjusted gross margins about 80.5% of sales and adjusted operating margin approaching 45% of sales.
https://thefly.com/landingPageNews.php?id=2816721
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.